Lida Tehrani

1.5k total citations
19 papers, 1.0k citations indexed

About

Lida Tehrani is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Genetics. According to data from OpenAlex, Lida Tehrani has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Cellular and Molecular Neuroscience and 3 papers in Genetics. Recurrent topics in Lida Tehrani's work include Neuroscience and Neuropharmacology Research (12 papers), Chemical Synthesis and Analysis (3 papers) and Molecular Sensors and Ion Detection (3 papers). Lida Tehrani is often cited by papers focused on Neuroscience and Neuropharmacology Research (12 papers), Chemical Synthesis and Analysis (3 papers) and Molecular Sensors and Ion Detection (3 papers). Lida Tehrani collaborates with scholars based in United States. Lida Tehrani's co-authors include Nicholas D. P. Cosford, Mark A. Varney, Sara Rao, Jeffrey Roppe, Edwin J. Schweiger, Jesse Brodkin, Linda J. Bristow, Xiaohui Jiang, Jeffrey Anderson and Nicholas D. Smith and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Neuropsychopharmacology.

In The Last Decade

Lida Tehrani

19 papers receiving 975 citations

Peers

Countries citing papers authored by Lida Tehrani

Since Specialization

Citations

This map shows the geographic impact of Lida Tehrani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lida Tehrani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lida Tehrani more than expected).

Fields of papers citing papers by Lida Tehrani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lida Tehrani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lida Tehrani. The network helps show where Lida Tehrani may publish in the future.

Co-authorship network of co-authors of Lida Tehrani

This figure shows the co-authorship network connecting the top 25 collaborators of Lida Tehrani. A scholar is included among the top collaborators of Lida Tehrani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lida Tehrani. Lida Tehrani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation 2023 ·Journal of Medicinal Chemistry ·Stephen H. Norris, (unknown), (unknown), Dehua Huang, Gody Khambatta, (unknown), Surendra Kumar Nayak, Joseph D. Meiring, Samantha Reiss, Shuichan Xu, Lihong Shi, Brandon Whitefield, Matthew D. Alexander, (unknown), Matthew Correa, Lida Tehrani, Joshua D. Hansen, (unknown), Deborah S. Mortensen	30
2	Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity 2021 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Dale Robinson, Sogole Bahmanyar, Lida Tehrani, Kimberly E. Fultz, Rama Krishna Narla, Xiaohui Peng, Tam Tran, Julius Apuy, Laurie A. LeBrun, Katerina Leftheris, John F. Boylan, Dan Zhu, Jennifer R. Riggs	5
3	Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy 2019 ·Journal of Medicinal Chemistry ·Jennifer R. Riggs, (unknown), (unknown), Dale Robinson, Lida Tehrani, Mark A. Nagy, Kimberly E. Fultz, Rama Krishna Narla, Xiaohui Peng, Tam Tran, Ashutosh A. Kulkarni, Sogole Bahmanyar, Kevin R. Condroski, Barbra Pagarigan, Gustavo Fenalti, Laurie A. LeBrun, Katerina Leftheris, Dan Zhu, John F. Boylan	17
4	The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity 2008 ·Bioorganic & Medicinal Chemistry Letters ·Tony Siu, Yiwei Li, Johnny Nagasawa, Jun Liang, Lida Tehrani, Peter Chua, Raymond E. Jones, Deborah Defeo-Jones, Stanley F. Barnett, R. Robinson	13
5	3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Lida Tehrani, Nicholas D. Smith, Dehua Huang, Steve F. Poon, Jeffrey Roppe, T. Jon Seiders, Deborah F. Chapman, Janice Chung, Merryl Cramer, Nicholas D. P. Cosford	10
6	Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Margaret Bradbury, Una C. Campbell, (unknown), Deborah F. Chapman, Chris King, Lida Tehrani, Nicholas D. P. Cosford, Jeff Anderson, Mark A. Varney, Alison M. Strack	75
7	Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Peter Chua, Johnny Nagasawa, Leo Bleicher, Benito Muñoz, Edwin J. Schweiger, Lida Tehrani, Jeffrey Anderson, Merryl Cramer, Janice Chung, Mitchell D. Green, Chris King, (unknown), Nicholas D. P. Cosford	11
8	2‐{2‐[3‐(Pyridin‐3‐yloxy)phenyl]‐2H‐tetrazol‐5‐yl}pyridine: A Highly Potent, Orally Active, Metabotropic Glutamate Subtype 5 (mGlu5) Receptor Antagonist. 2005 ·ChemInform ·Dehua Huang, Steve F. Poon, Deborah F. Chapman, Janice Chung, Merryl Cramer, Thomas S. Reger, Jeffrey Roppe, Lida Tehrani, Nicholas D. P. Cosford, Nicholas D. Smith	1
9	2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist 2004 ·Bioorganic & Medicinal Chemistry Letters ·Dehua Huang, Steve F. Poon, Deborah F. Chapman, Janice Chung, Merryl Cramer, Thomas S. Reger, Jeffrey Roppe, Lida Tehrani, Nicholas D. P. Cosford, Nicholas D. Smith	25
10	5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3′-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity 2004 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey Roppe, Bowei Wang, Dehua Huang, Lida Tehrani, Theodore M. Kamenecka, Edwin J. Schweiger, Jeffery J. Anderson, Jesse Brodkin, Xiaohui Jiang, Merryl Cramer, Janice Chung, (unknown), Benito Muñoz, Nicholas D. P. Cosford	41
11	The Behavioral Profile of the Potent and Selective mGlu5 Receptor Antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in Rodent Models of Anxiety 2004 ·Neuropsychopharmacology ·(unknown), Jesse Brodkin, (unknown), Jeffery J. Anderson, (unknown), Lida Tehrani, Linda J. Bristow, Mark A. Varney, Nicholas D. P. Cosford	137
12	Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor 2004 ·Bioorganic & Medicinal Chemistry Letters ·Essa Hu, Peter Chua, Lida Tehrani, Johnny Nagasawa, Anthony B. Pinkerton, Blake A. Rowe, Jean‐Michel Vernier, John H. Hutchinson, Nicholas D. P. Cosford	12
13	Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity 2004 ·Bioorganic & Medicinal Chemistry Letters ·Nicholas D. Smith, Steve F. Poon, Dehua Huang, Mitchell Green, Christopher D. King, Lida Tehrani, Jeffrey Roppe, Janice Chung, (unknown), Merryl Cramer, Nicholas D. P. Cosford	12
14	[3H]-Methoxymethyl-MTEP and [3H]-Methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor 2003 ·Bioorganic & Medicinal Chemistry Letters ·Nicholas D. P. Cosford, Jeffrey Roppe, Lida Tehrani, Edwin J. Schweiger, T. Jon Seiders, (unknown), Sara Rao, Mark A. Varney	123
15	[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo Characterization 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Jeffery J. Anderson, Sara Rao, Blake A. Rowe, (unknown), (unknown), Deborah F. Chapman, Lida Tehrani, Margaret Bradbury, Nicholas D. P. Cosford, Mark A. Varney	93
16	3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: A Potent and Highly Selective Metabotropic Glutamate Subtype 5 Receptor Antagonist with Anxiolytic Activity 2002 ·Journal of Medicinal Chemistry ·Nicholas D. P. Cosford, Lida Tehrani, Jeffrey Roppe, Edwin J. Schweiger, Nicholas D. Smith, Jeffrey Anderson, Linda J. Bristow, Jesse Brodkin, Xiaohui Jiang, Ian A. McDonald, Sara Rao, Mark Washburn, Mark A. Varney	348
17	Substituted Xanthines, Pteridinediones, and Related Compounds as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor α 1996 ·Journal of Medicinal Chemistry ·Howard B. Cottam, Hsiencheng Shih, Lida Tehrani, D B Wasson, Dennis A. Carson	41
18	ChemInform Abstract: Substituted Xanthines, Pteridinediones, and Related Compounds as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor α. 1996 ·ChemInform ·Howard B. Cottam, (unknown), Lida Tehrani, D B Wasson, Dennis A. Carson	6
19	Synthesis and physicochemical characterization of the lanthionine analog of somatostatin[1?14] 1994 ·Letters in Peptide Science ·(unknown), Giuseppe Melacini, Qin Zhu, Lida Tehrani, Murray Goodman	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact